Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,294 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,294 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $35.14, for a total value of $115,751.16. Following the transaction, the insider directly owned 58,584 shares in the company, valued at approximately $2,058,641.76. This represents a 5.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

Shares of NASDAQ CSTL opened at $35.48 on Thursday. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -53.76 and a beta of 0.99. The business has a 50 day simple moving average of $29.79 and a 200-day simple moving average of $25.57.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million for the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. As a group, equities research analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Institutional Trading of Castle Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Advisors Capital Management LLC acquired a new position in Castle Biosciences during the second quarter worth about $5,681,000. BlackRock Inc. acquired a new stake in Castle Biosciences in the 2nd quarter valued at about $78,513,000. Quantinno Capital Management LP boosted its position in shares of Castle Biosciences by 387.3% during the 1st quarter. Quantinno Capital Management LP now owns 45,476 shares of the company’s stock valued at $1,116,000 after purchasing an additional 36,144 shares in the last quarter. Summit Partners Public Asset Management LLC boosted its position in shares of Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after purchasing an additional 658,725 shares in the last quarter. Finally, SummitTX Capital L.P. grew its stake in shares of Castle Biosciences by 285.0% in the 1st quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock worth $1,646,000 after purchasing an additional 49,623 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. BTIG Research raised their target price on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a research note on Friday, May 29th. Finally, Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.